{"ticker": {"uuid": "ac43da49-8598-4402-a91b-9eb219437cdb", "symbol": "ONCOZ", "name": "OncoZenge AB (publ)", "exchange": "STO", "country": "SE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "OncoZenge Extends Payment Deadline In Directed Share Issue", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNSFYwYURDcEF5S3I2R3RtSXpHb1lObnp4R1VFQ3ljWlgzT2ltQVozWFhybHY3VTItYmJiVnVoOUVlSzlETGdnazh6dDlqamVuNkFuMkRjN2xXMmdjMHBjMFN2TW42WlM4a011SWJGWVNzSGVQaC1obC01REgwVnI3WkM3eWdEcWdzQWdCSGVfdEtibnk0cVpvUUFhRHY2bHRycUU3bkRfRnh5NWhPbXlxZ3UxdDlyVUZYa0IzaDVtVENEOU00QlZB?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T05:50:00+00:00", "published_display": "13 Jul 2026 05:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge has received partial payment of SEK 5.0 million for subscription proceeds in directed share issue and extends payment deadline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxNb2VrWUY3MmRVQzNibldQWGZhOHc1dTVmcS1VWTZZNUFTTjNFNnFUemdKblNFeE42d2JWbjRyMnVSNm1UejBYSHM5SHFRcFM2dGRZMV9zRV94ZFliLXJ2X3AxcVJfa3p3N2FqbzE3UjdMd3Y3elFHQkhtU015OVNjYUlUY0QtdTR2LUJSYWtERzEwR0kyTTJYdUVBSUx5bVJranJ4bHJiNTd0RXNqU2tJb2pUbkFqVU1qcjFwUXlmaHdNT2dvQUZNMExKTlZpekc1d1lCN3VmejhscVd6Tm1KVjhRclo2YTB4NHNxVWNETER0WmxoNVpyNHd5Q1ZUdWQ0Y0p6VzRuVC0tZ2NLdE56eWdLVXZJR0xnUU1mekhhWDVqQS1nMFA2MTFR?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T15:15:00+00:00", "published_display": "10 Jul 2026 15:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge Extends the Payment Deadline for Subscription Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNTTlLOUN6NDlXZlJPZUNmUTAweGpmRzBrVDVHRVRVLTFEYk00cGFGOURXV2RBUVB0Rk9lb2YtNU9mU0xVNEpYVFV1cXpRaFhGLXZOMkFRT010b1hQbzJjR1dZYU16WlJ2RGl2NFdLWHByRUFUV2lSbFZtUFBTbDRqbGU3NkhLenFfR2NaT3RRLThYNDAzZ3ZDWS1NVE9iRHVRTE1yTHpLMnozd2Q2YTBRaDRaQ1MxNVRZenBkTkVXdWFFd3JLN0YxZm9R?oc=5", "source_name": "TradingView", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of OncoZenge AB \u2013 OMXSTO:ONCOZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTFJkRzJrSnNKcGdvQi10Qy02SEJ6VDZkWDVvbVJQSDRXYkVTeDRhZi1lR2F2dDRCbjFzZjRWdnd1RkcwTFJNMjlvdThESnpmZ19PbFoyc0dyVDh1NkRkY2k3dmJjZTdEMHpQbXVCZ29Kc1NpZjgtT2NHQ3hKNUxWN0ROWV93REdjZ1dqRTg1RUVrRUJJSVRUS3dJb1RFUWM?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T19:09:30+00:00", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge AB Actuals & Estimates (OMXSTO:ONCOZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNT2YyMzBlSnRPdFp2c2lQOTRCRjRYQ0JKZk1vWUpOOVZrRXdxMG9QTWhDYUpQR2ljWk00ekkwMEs3NWtkdVhmMjdZLU50Ui01RUVieVBwdU5kRTVCSUppQUxCUFk0bFV1SkFTS1U2Vjk4eDVhVklRc0Jhc3NxSWdYS3p3WHpTY2M?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T16:06:24+00:00", "published_display": "25 Jun 2026 16:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPUFBBT3pYMnQxUEQzRFpaclA4Wm5VMFFuTDdmWFNzWTUtQ0ZZX0FfeHJfUzBjdjc3MWVfOHZhWEpITFVFa3dmcDNzYkZFUlRrTGZtOEZUNVdldi01TmtDcU90dm1MbnppWUlWV0kxNGlUVHdTbjZNd3RmRTJicm5SOWI3Q3NEd1ZGOW5xZHhBTERkMGNLMVZFVWpjQmdvc0FWa0Z0TklmV1JtdTU2c0E4TGY4NkNZYTFEN3AzYkdoQVRHbHZiM0h5T2E1d2NuYVl6cklIQ0M0U2g?oc=5", "source_name": "TradingView", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "OncoZenge Extends Payment Deadline In Directed Share Issue", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNSFYwYURDcEF5S3I2R3RtSXpHb1lObnp4R1VFQ3ljWlgzT2ltQVozWFhybHY3VTItYmJiVnVoOUVlSzlETGdnazh6dDlqamVuNkFuMkRjN2xXMmdjMHBjMFN2TW42WlM4a011SWJGWVNzSGVQaC1obC01REgwVnI3WkM3eWdEcWdzQWdCSGVfdEtibnk0cVpvUUFhRHY2bHRycUU3bkRfRnh5NWhPbXlxZ3UxdDlyVUZYa0IzaDVtVENEOU00QlZB?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T05:50:00+00:00", "published_display": "13 Jul 2026 05:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge has received partial payment of SEK 5.0 million for subscription proceeds in directed share issue and extends payment deadline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxNb2VrWUY3MmRVQzNibldQWGZhOHc1dTVmcS1VWTZZNUFTTjNFNnFUemdKblNFeE42d2JWbjRyMnVSNm1UejBYSHM5SHFRcFM2dGRZMV9zRV94ZFliLXJ2X3AxcVJfa3p3N2FqbzE3UjdMd3Y3elFHQkhtU015OVNjYUlUY0QtdTR2LUJSYWtERzEwR0kyTTJYdUVBSUx5bVJranJ4bHJiNTd0RXNqU2tJb2pUbkFqVU1qcjFwUXlmaHdNT2dvQUZNMExKTlZpekc1d1lCN3VmejhscVd6Tm1KVjhRclo2YTB4NHNxVWNETER0WmxoNVpyNHd5Q1ZUdWQ0Y0p6VzRuVC0tZ2NLdE56eWdLVXZJR0xnUU1mekhhWDVqQS1nMFA2MTFR?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T15:15:00+00:00", "published_display": "10 Jul 2026 15:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge Extends the Payment Deadline for Subscription Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNTTlLOUN6NDlXZlJPZUNmUTAweGpmRzBrVDVHRVRVLTFEYk00cGFGOURXV2RBUVB0Rk9lb2YtNU9mU0xVNEpYVFV1cXpRaFhGLXZOMkFRT010b1hQbzJjR1dZYU16WlJ2RGl2NFdLWHByRUFUV2lSbFZtUFBTbDRqbGU3NkhLenFfR2NaT3RRLThYNDAzZ3ZDWS1NVE9iRHVRTE1yTHpLMnozd2Q2YTBRaDRaQ1MxNVRZenBkTkVXdWFFd3JLN0YxZm9R?oc=5", "source_name": "TradingView", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of OncoZenge AB \u2013 OMXSTO:ONCOZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTFJkRzJrSnNKcGdvQi10Qy02SEJ6VDZkWDVvbVJQSDRXYkVTeDRhZi1lR2F2dDRCbjFzZjRWdnd1RkcwTFJNMjlvdThESnpmZ19PbFoyc0dyVDh1NkRkY2k3dmJjZTdEMHpQbXVCZ29Kc1NpZjgtT2NHQ3hKNUxWN0ROWV93REdjZ1dqRTg1RUVrRUJJSVRUS3dJb1RFUWM?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T19:09:30+00:00", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge AB Actuals & Estimates (OMXSTO:ONCOZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNT2YyMzBlSnRPdFp2c2lQOTRCRjRYQ0JKZk1vWUpOOVZrRXdxMG9QTWhDYUpQR2ljWk00ekkwMEs3NWtkdVhmMjdZLU50Ui01RUVieVBwdU5kRTVCSUppQUxCUFk0bFV1SkFTS1U2Vjk4eDVhVklRc0Jhc3NxSWdYS3p3WHpTY2M?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T16:06:24+00:00", "published_display": "25 Jun 2026 16:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPUFBBT3pYMnQxUEQzRFpaclA4Wm5VMFFuTDdmWFNzWTUtQ0ZZX0FfeHJfUzBjdjc3MWVfOHZhWEpITFVFa3dmcDNzYkZFUlRrTGZtOEZUNVdldi01TmtDcU90dm1MbnppWUlWV0kxNGlUVHdTbjZNd3RmRTJicm5SOWI3Q3NEd1ZGOW5xZHhBTERkMGNLMVZFVWpjQmdvc0FWa0Z0TklmV1JtdTU2c0E4TGY4NkNZYTFEN3AzYkdoQVRHbHZiM0h5T2E1d2NuYVl6cklIQ0M0U2g?oc=5", "source_name": "TradingView", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 58, "total_relevant": 6, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 6, "score": 50, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 6.59, "latest_week": "2026-07-10", "one_week_move": -8.7, "four_week_move": -17.0, "twelve_week_move": 14.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.984277, "market_dynamics_buy_signal": false, "relative_strength": -3.033692, "fair_value_gap": 28.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 46.0829, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.7% over one week, -17.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 6}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-8.7% over one week, -17.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "OncoZenge Extends Payment Deadline In Directed Share Issue"}], "updated_at": "2026-07-17T13:22:26.341760+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}